A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Mar 2015

At a glance

  • Drugs Linsitinib (Primary)
  • Indications Adrenal cancer; Adrenocortical carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms GALACCTIC
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 30 May 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 23 Oct 2012 Planned number of patients changed from 135 to 165 as reported by European Clinical Trials Database.
    • 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top